Compounds > celecoxib

celecoxib and aprepitant

celecoxib has been researched along with aprepitant in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Hagmann, WK1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Green, C; Hewlett, E; Hughes, M; Padgett, D; Schwartz, L; Tessier, J; Zhao, W1
Halatsch, ME; Karpel-Massler, G; Kast, RE1
He, H; Jin, X; Liu, B; Lu, G; Qin, L; Shao, Y; Shen, Z; Wang, X; Xu, T; Zhang, X; Zhao, Z1
Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO1
Kast, RE1

Reviews

2 review(s) available for celecoxib and aprepitant

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive.
    International journal of molecular sciences, 2023, Oct-23, Volume: 24, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Bone Neoplasms; Celecoxib; Humans; Osteosarcoma

2023

Other Studies

7 other study(ies) available for celecoxib and aprepitant

ArticleYear
The many roles for fluorine in medicinal chemistry.
    Journal of medicinal chemistry, 2008, Aug-14, Volume: 51, Issue:15

    Topics: Animals; Chemistry, Pharmaceutical; Enzyme Inhibitors; Fluorine; Fluorine Compounds; Humans; Protein Binding; Stereoisomerism

2008
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis.
    Infection and immunity, 2007, Volume: 75, Issue:4

    Topics: Animals; Antigens, Bacterial; Aprepitant; Bacillus anthracis; Bacterial Toxins; Capillary Permeability; Celecoxib; Cell Degranulation; Cell Line; Disease Models, Animal; Edema; Enzyme Inhibitors; Histamine; Histamine H1 Antagonists; Humans; Indomethacin; Injections, Intradermal; Mast Cells; Morpholines; Neurokinin-1 Receptor Antagonists; Prostaglandin Antagonists; Prostaglandins; Pyrazoles; Pyrilamine; Rabbits; Substance P; Sulfonamides; Tachykinins

2007
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
    Oncotarget, 2014, Sep-30, Volume: 5, Issue:18

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auranofin; Brain Neoplasms; Captopril; Celecoxib; Dacarbazine; Disulfiram; Glioblastoma; Humans; Itraconazole; Molecular Targeted Therapy; Morpholines; Neoplasm Recurrence, Local; Pyrazoles; Ritonavir; Sertraline; Signal Transduction; Sulfonamides; Temozolomide; Treatment Outcome

2014
Specific inhibition of ICAM-1 effectively reduces bladder inflammation in a rat model of severe non-bacterial cystitis.
    Scientific reports, 2016, 10-26, Volume: 6

    Topics: Animals; Antibodies; Aprepitant; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Cystitis, Interstitial; Cytokines; Female; Immunotherapy; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Mast Cells; Morpholines; Neurokinin-1 Receptor Antagonists; Protamines; Rats; Rats, Sprague-Dawley; Urinary Bladder

2016
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
    Journal of cancer research and clinical oncology, 2019, Volume: 145, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Auranofin; Brain Neoplasms; Captopril; Celecoxib; Disulfiram; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Glioblastoma; Humans; Itraconazole; Mice; Mice, SCID; Minocycline; Neoplastic Stem Cells; Quetiapine Fumarate; Reproducibility of Results; Sertraline; Signal Transduction; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019